{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Spontaneous+Urticaria", "query": { "condition": "Chronic Spontaneous Urticaria" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Spontaneous+Urticaria&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:47:16.467Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05032157", "title": "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "LOU064 (blinded)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LOU064 (open-label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 455, "start_date": "2021-12-01", "completion_date": "2024-01-05", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032157" }, { "nct_id": "NCT06072157", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants", "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "AK006-IV", "type": "DRUG" }, { "name": "Placebo-IV", "type": "DRUG" }, { "name": "AK006-SC", "type": "DRUG" }, { "name": "Placebo-SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 136, "start_date": "2023-08-28", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 19, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072157" }, { "nct_id": "NCT07358364", "title": "Remibrutinib in Real-world Clinical Practice", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3280, "start_date": "2026-02-02", "completion_date": "2031-10-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 1, "location_summary": "Kirksville, Missouri", "locations": [ { "city": "Kirksville", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07358364" }, { "nct_id": "NCT06927999", "title": "An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urticaria Chronic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "0.5 mg epinephrine", "type": "DRUG" }, { "name": "1 mg epinephrine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ARS Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 42, "start_date": "2025-07-09", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 2, "location_summary": "Glenview, Illinois • Cincinnati, Ohio", "locations": [ { "city": "Glenview", "state": "Illinois" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06927999" }, { "nct_id": "NCT03661866", "title": "A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis", "Alopecia Areata", "Hidradenitis Suppurativa", "Vitiligo", "Psoriasis", "Chronic Spontaneous Urticaria" ], "interventions": [], "intervention_types": [], "sponsor": "Target PharmaSolutions, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15000, "start_date": "2018-12-21", "completion_date": "2050-12", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03661866" }, { "nct_id": "NCT01008592", "title": "The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rhinitis", "Urticaria" ], "interventions": [ { "name": "levocetirizine or placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2009-04", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2017-02-28", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008592" }, { "nct_id": "NCT01292473", "title": "A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Omalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 323, "start_date": "2011-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2013-10-11", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 36, "location_summary": "La Jolla, California • Los Angeles, California • Redwood City, California + 31 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01292473" }, { "nct_id": "NCT05677451", "title": "24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "LOU064 (blinded)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2023-07-11", "completion_date": "2032-03-30", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 12, "location_summary": "Bakersfield, California • San Diego, California • Miami, Florida + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Glenview", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05677451" }, { "nct_id": "NCT05030311", "title": "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "LOU064 25 mg (b.i.d)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LOU064 25 mg (b.i.d) as a tablet.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2021-11-30", "completion_date": "2024-01-19", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 26, "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05030311" }, { "nct_id": "NCT03494881", "title": "Mepolizumab for the Treatment of Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Nucala", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-07-30", "completion_date": "2025-02-25", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-22T09:47:16.467Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03494881" } ] }